Pharmacy Medical Policy
Opioid and Opioid Combination Medication Management

Table of Contents
- Policy: Commercial
- Information Pertaining to All Policies
- Policy: Medicare
- Policy History
- References
- Forms

Policy Number: 102
BCBSA Reference Number: None

Related Policies
- Quality Care Dosing guidelines apply to the following medications and can be found in Medical Policy #621

Policy
Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity

Note: All requests for outpatient retail pharmacy for indications listed and not listed on the medical policy guidelines may be submitted to BCBSMA Clinical Pharmacy Operations by completing the Prior Authorization Form on the last page of this document. Physicians may also call BCBSMA Pharmacy Operations department at (800)366-7778 to request a prior authorization/formulary exception verbally. Physicians may also submit requests for retail pharmacy exceptions via the web using Express PA which can be found on the BCBSMA provider portal or directly on the web at https://provider.express-path.com. Patients must have pharmacy benefits under their subscriber certificates.

Please refer to the chart below for the formulary and step status of the medications affected by this policy.

<table>
<thead>
<tr>
<th>Standard Formulary</th>
<th>Short-Acting Opioids (including generic products where applicable)†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alfenta® (alfentanil)</td>
<td>Magnacet® (oxycodone/APAP)</td>
</tr>
<tr>
<td>Astramorph®/PF (morphine (systemic))</td>
<td>Margesic® - H (hydorcodone/APAP)</td>
</tr>
<tr>
<td>Capital® and Codeine (APAP and Codeine)</td>
<td>Maxidone® (hydrocodone/APAP)</td>
</tr>
<tr>
<td>Cocet/Plus™ (codeine/APAP)</td>
<td>Meperitab® (meperidine)</td>
</tr>
<tr>
<td>Co-gesic® (hydrocodone/APAP)</td>
<td>Norco® (hydrocododone/APAP)</td>
</tr>
<tr>
<td>Demerol® (meperidine)</td>
<td>Nucynta® (tapentadol)**</td>
</tr>
<tr>
<td>Dilaudid® (hydromorphone)</td>
<td>Opana® (oxymorphone)**</td>
</tr>
<tr>
<td>Duramorph (morphine (systemic))**</td>
<td>Oxecta™ (oxycodone)**</td>
</tr>
<tr>
<td>Hycet® (hydrocodone/APAP)</td>
<td>Panior® SS</td>
</tr>
</tbody>
</table>
Hydrogesic (dihydrocodeine/APAP) | Percocet® (oxycodone/APAP)** | Xodol® (hydrocodone/APAP)
---|---|---
Ibudone™ (hydrocodone/ibuprofen) | Percodan® (oxycodone/aspirin) | Zamicet™ (hydrocodone/APAP)
Infumorph (morphine systemic) | Polygesic (hydrocodone/APAP) | Zerlor (dihydrocodeine/APAP/caffeine)
Lorcet® (hydrocodone/APAP) | Primlev™ (oxycodone/APAP) | Zolvit® (hydrocodone/APAP)
| | | Zydone® (hydrocodone/APAP)

**Non-formulary medications are covered when a formulary exception request is submitted to BCBSMA Pharmacy Operations and criteria below are met.

† New medications released to market in these classes will be added to the policy as part of the New Drug Approval process.

OPIOID AND OPIOID COMBINATION PRESCRIPTIONS ARE EXCLUDED THROUGH THE MAIL ORDER PHARMACY BENEFIT.

Description
Opioids are powerful tools for the relief of pain. They are however associated with the risks of addiction and diversion for non-medical purposes. The purpose of this policy is to use current medical literature to establish processes to promote the effective use of opioids in pain management and to prevent inadvertent addiction and deter diversion. It is our expectation that members using opioids will be compliant with this policy and that coverage for associated medical services is dependent on this compliance.

The use of opioids is associated with the risk of addiction. Informing patients of this risk is an important activity in the evidence based use of opioids. Ideally this informed consent, with a risk assessment of addiction potential, is given and obtained prior to an initial prescription for any opioid. A treatment plan including a clear diagnosis, explicit goals, and exploration of other treatment options should exist. If members are to receive opioids chronically, a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances should exist. Chronic prescribing of opioids should be done by a single designated prescriber group and medications should be obtained by the member at one pharmacy or pharmacy chain.

Urine drug testing (UDT) is medically necessary and plays an integral role of effective medical management of opioids. It should be used appropriately to inform clinical decision making. See policy # 674 for additional details.

Please refer to Medical Policy #113 for coverage of oral/transmucosal Fentanyl products.

Quality Care Dosing guidelines may apply to the following medications and can be found in Medical Policy #621.
**Short-Acting Medications:**
We may cover short-acting opioids listed in the chart above when the following criteria are met:
- The member has a diagnosis of cancer.
  OR
- The prescription is written by an oncologist or oncology prescriber
  OR
- The member is receiving opioids as part of end of life care.

For all other requests:
- We may cover short-acting formulary opioids listed in the chart above for up to one initial 7 day supply without prior authorization.
- We may cover up to two additional 7 days supply of short-acting formulary opioids listed in the chart above within 60 days of the original prescription without prior authorization.
- After the initial three prescriptions or an excess of 21 days within 60 days, prior authorization is required and we may cover additional treatment with short-acting formulary opioids within 60 days of the original prescription when the following criteria are met:
  - The prescriber certifies there is an active treatment plan that includes but is not limited to a specific treatment objective and the use of other pharmacological and non-pharmacological agents for pain relief as appropriate.
  - The prescriber certifies there has been an informed consent document signed and an addiction risk assessment has been performed.
  - The prescriber certifies that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists.
  - The prescriber certifies that a prescribing group and a preferred pharmacy chain has been agreed upon by the prescriber and the member.

For non-formulary short acting opioids, requests must meet criteria above and the member must have had a previous treatment failure with or a contraindication to two covered formulary alternatives.

If the above criteria are met, approval may be given for continued short-acting and/or initiation of long-acting opioid medication therapy for up to 1 year. This authorization may cover the use of any of the short-acting or long-acting formulary opioids. Non-formulary medications will not be covered unless a formulary exception has been approved.

**Long-Acting Medications:**
We may cover long-acting opioids listed in the chart above when the following criteria are met:
- The member has a diagnosis of cancer.
  OR
- The prescription is written by an oncologist or oncology prescriber.
  OR
- The member is receiving opioids as part of end of life care.
- The request meets ALL of the following criteria:
  - There has been previous treatment failure with a short-acting opioid within the previous 60 days.
  - The prescriber certifies there is an active treatment plan that includes but is not limited to a specific treatment objective and the use of other pharmacological and non-pharmacological agents for pain relief as appropriate.
  - The prescriber certifies there has been an informed consent document signed and an addiction risk assessment performed.
  - The prescriber certifies that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists.
  - The prescriber certifies that a prescribing group and a preferred pharmacy chain has been agreed upon by the prescriber and the member.
For non-formulary long-acting opioids, requests must meet criteria above and has previous treatment failure with or a contraindication to two covered formulary alternatives.

If the above criteria are met, approval may be given for continued long-acting and/or initiation of short-acting opioid medications for up to 1 year. This authorization may cover the use of any of the long-acting or short-acting formulary opioids. Non-formulary medications will not be covered unless a formulary exception has been approved.

Individual Consideration
All our medical policies are written for the majority of people with a given condition. Each policy is based on medical science. For many of our medical policies, each individual’s unique clinical circumstances may be considered in light of current scientific literature. Physicians may send relevant clinical information for individual patients for consideration to:

Blue Cross Blue Shield of Massachusetts
Pharmacy Operations Department
25 Technology Place
Hingham, MA 02043
Tel: 1-800-366-7778
Fax: 1-800-583-6289

Managed Care Authorization Instructions
- Prior authorization is required for all outpatient sites of service
- For retail pharmacy requests, physicians may call BCBSMA Pharmacy Operations department to request a review for prior authorization for patients.
  - Pharmacy Operations: (800)366-7778
- For all outpatient sites of service, physicians may also fax or mail the attached form to the address above. The Formulary Exception/Prior Authorization form is included as part of this document for physicians to submit for patients.
- For all outpatient sites of service, physicians may also submit requests for retail pharmacy exceptions via the web using Express PAth which can be found on the BCBSMA provider website or directly on the web at https://provider.express-path.com

PPO and Indemnity Authorization Instructions
- Prior authorization is required when these medications are processed under the retail pharmacy benefit and home infusion therapy benefit.
- Prior authorization is not required when these drugs are purchased by the physician and administered in the office in accordance with this medical policy.
- For retail pharmacy requests, physicians may call BCBSMA Pharmacy Operations department to request a review for prior authorization for patients.
  - Pharmacy Operations: (800)366-7778
- Physicians may also fax or mail the attached form to the address above. The Formulary Exception/Prior Authorization form is included as part of this document for physicians to submit for patients.
- Physicians may also submit requests for retail pharmacy exceptions via the web using Express PAth which can be found on the BCBSMA provider website or directly on the web at https://provider.express-path.com

Policy History

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>10/2017</td>
<td>Updated to add AG Buprenorphine Patch &amp; Butrans® to the formulary.</td>
</tr>
<tr>
<td>6/2017</td>
<td>Updated address for Pharmacy Operations and added Morphabond™ ER.</td>
</tr>
<tr>
<td>4/2017</td>
<td>Updated to add Arymo™ ER to the long acting part of the policy.</td>
</tr>
<tr>
<td>1/1/2017</td>
<td>Updated to make some format changes.</td>
</tr>
<tr>
<td>8/2016</td>
<td>Updated to align with Massachusetts Opioid law and shortened criteria for short-acting Opioids.</td>
</tr>
<tr>
<td>4/2016</td>
<td>Updated to add Belbuca to Long acting section of policy</td>
</tr>
<tr>
<td>8/2015</td>
<td>Updated Request form title</td>
</tr>
<tr>
<td>1/2015</td>
<td>Updated to remove UDT and added Zohydro ER and Verdocet</td>
</tr>
</tbody>
</table>
References

To request prior authorization using the Massachusetts Standard Form for Medication Prior Authorization Requests (eForm), click the link below: